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Abstract
Background: Hyperhomocysteinemia (HHcy) causes increased oxidative stress and is an independent risk factor for
cardiovascular disease. Oxidative stress is now believed to be a major contributory factor in the development of
non alcoholic fatty liver disease, the most common liver disorder worldwide. In this study, the changes which
occur in homocysteine (Hcy) metabolism in high fat-diet induced non alcoholic fatty liver disease (NAFLD) in rats
were investigated.
Methods and results: After feeding rats a standard low fat diet (control) or a high fat diet (57% metabolisable
energy as fat) for 18 weeks, the concentration of homocysteine in the plasma was significantly raised while that of
cysteine was lowered in the high fat as compared to the control diet fed animals. The hepatic activities of
cystathionine b-synthase (CBS) and cystathionine g-lyase (CGS), the enzymes responsible for the breakdown of
homocysteine to cysteine via the transsulphuration pathway in the liver, were also significantly reduced in the high
fat-fed group.
Conclusions: These results indicate that high fat diet-induced NAFLD in rats is associated with increased plasma
Hcy levels caused by down-regulation of hepatic CBS and CGL activity. Thus, HHcy occurs at an early stage in high
fat diet-induced NAFLD and is likely to contribute to the increased risk of cardiovascular disease associated with
the condition.
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Background
Non alcoholic fatty liver disease (NAFLD) is the most
common liver disorder in the world, and in obesity, type
2 diabetes and related metabolic diseases, its incidence
reaches 70-90% [1]. The disease is characterised by the
accumulation of triacylglycerol (TG) inside liver cells,
and the condition can progress into more serious liver
disease, such as non alcoholic steatohepatitis (NASH),
liver fibrosis, cirrhosis, and more rarely, liver carcinoma
[1]. Although it is known that progression of the disease
is more likely to occur in patients with metabolic dis-
eases [2], the factors involved are not well understood.
However, oxidative stress coupled with insulin resistance
is believed to play an important role [3].
Current evidence indicates that insulin resistance
causes oxidative stress via increased oxidation in the
liver, raised formation of reactive oxygen species, higher
levels of hepatic lipid peroxidation, protein oxidation and
pro-inflammatory cytokine production and decreased
antioxidant capacity in the plasma [3-7]. Since the hepa-
tic steatosis in NAFLD is believed to follow from the
development of insulin resistance, oxidative stress
is now considered to be one of the major causes of
NAFLD [8,9].
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associated with accelerated atherosclerosis [10], but the
underlying mechanisms are not well understood. Mod-
erately raised plasma levels of homocysteine (Hcy) have
been found to be associated with atherosclerosis devel-
opment, and hyperhomocysteinemia (HHcy) is consid-
ered to be an independent risk factor for cardiovascular
disease [11,12]. Hcy is a thiol-containing amino acid
involved in the metabolism of methionine in the liver.
Methionine from dietary sources is converted to S-ade-
nosyl methionine (SAM) by methionine adenosyl trans-
ferase (MAT). SAM is the methyl donor in most
biological methylation reactions, and various methyl-
transferases (eg phosphatidyl-ethanolamine N-methyl-
transferase (PEMT) and glycine N-methyltransferase
(GNMT)) are involved in its usage for the formation of
phospholipids, myelin, and other macromolecules [12].
The product of the methyl transfer reactions is S-adeno-
syl homocysteine (SAH), which is then hydrolyzed to
Hcy. Once formed, Hcy may be either remethylated
to methionine (methionine cycle) or metabolised to
cysteine (Cys) in a two step pathway catalysed by the
enzymes cystathionine b-synthase (CBS) and cystathio-
nine g-lyase (CGL) (the transsulphuration pathway)
[12,13]. HHcy is known to be associated with athero-
sclerosis and other pathologies, and oxidative stress, due
to NADPH oxidase or NO synthase dependent genera-
tion of superoxide anion combined with a decrease in
antioxidant enzyme activity, is thought to be a major
factor in its effects [11,12]. In particular, when HHcy is
due to disorders of the transsulphuration pathway, it
associates with a reduced supply of Cys for the forma-
tion of the antioxidant glutathione (GSH) [13]. It has
been reported that HHcy caused by CBS deficiency
leads to disturbances in the regulation of lipid metabo-
lism and fat accumulation in the liver [14,15]. Moreover,
plasma Hcy is elevated in patients with NAFLD, and is a
predictor of steatohepatitis [16].
Our previous work has shown that feeding rats a high
fat diet (57% of energy from fat) induces insulin resis-
tance, hypertriglyceridemia, hepatic steatosis and liver
damage, which are characteristic of NAFLD and thus
provides a suitable model for the early stages of the dis-
ease [17,18]. In the present study, we have used this
model to test the hypothesis that high fat diet-induced
NAFLD in rats modifies hepatic Hcy metabolism via
modulation of the transsuphuration pathway.
Methods
Animals and diets
Male Wistar rats (200 g) (Harlan, S. Pietro al Natisone,
Italy) were housed individually and allowed food and
water ad libitum. All procedures conformed to the
Guidelines of the European Community Council for
animal care and use and to Decree 116/92, the Italian
enforcement of the European Directive 86/609/EEC.
The experimental protocol was approved by the Animal
Care Ethics Committee of the Istituto Superiore di
Sanità (ISS) and, according to the national law require-
ment the communication of the study has been sent by
the ISS to the Animal Welfare Office ( Office VI) of the
Italian Minister of Health (Communication Protocol
Number 983/SSA/07). Rats were fed a standard low fat
diet (4.3% fat, 10% of the metabolizable energy; control
diet, 6 rats) or a diet containing 35% fat (31.6% satu-
rated fat and 3.2% unsaturated fat, 57% of the metabo-
lizable energy [18]; high fat diet, 4 rats) (Mucedola srl,
Settimo Milanese, Italy) for 18 weeks. All rats were then
sacrificed after fasting overnight. Blood samples were
collected via heart puncture with the rats under terminal
anesthesia (Acepromazine 2.5 mg/kg + Xylazine 1 -
5 mg/kg im) and centrifuged (3,500 rpm, 15 min, 6°C)
to obtain the plasma. Livers were excised, washed with
cold physiological saline (0.9%), samples (200 mg)
were homogenised in methanol (5 ml) and the lipids
extracted [19].
Determination of CBS and CGL activities
CBS activity was assayed by a modification of the proce-
dure of Mudd et al. [20]. Liver tissue (200 mg) was
homogenized in ice-cold KH2PO4 (50 mM, pH 7.5),
centrifuged (14,000 g, 10 min, 4°C) and the supernatant
collected. L-Hcy (3 μmol) was added to the reaction
mixture (100 mM Tris, pH 8.6; pyridoxal 5’-phosphate,
0.2 μmol; liver 14,000 g supernatant, 400-600 μg protein;
0.5 mg/ml BSA; L-[3-
14C]serine (GE Healthcare, Amer-
sham, UK), 0.06 μCi; serine, 2 μmol; L-cystathionine, 0.2
μmol) and incubated at 37°C for 90 min. The reaction
was terminated with trifluoroacetic acid (10%, 200 μl).
After centrifugation (10,000 g,5m i n ) ,t h e[
14C]
cystathionine product was isolated using AG-50W-X8
resin (Bio-Rad) and eluted with 6 M NH4OH. Radioac-
tivity was determined by scintillation counting. The
assay was linear with time and protein concentration in
t h er a n g e su s e d .1u n i to fC B S=t h a tf o r m i n g1n m o l
cystathionine per hour at 37°C. CGL activity was mea-
sured in cytosol as in [21]. Liver tissue (200 mg) was
homogenized in ice-cold KH2PO4 (30 mM, pH 6.9),
centrifuged (28,000 g,30 min, 4°C) and the supernatant
collected. Cystathionine (2 μmol) was added to the
reaction mixture (Tris-HCl buffer, pH 8.4, 50 μmol; pyr-
idoxal 5’-phosphate, 0.125 μmol; liver 28,000 g superna-
tant, 400-600 μg protein) and incubated for 30 min at
37°C. After placing the tubes in ice to terminate the
reaction, dithiothreitol (5 μmol/tube) was added. Cys
was determined spectrophotometrically using acid nin-
hydrin reagent (1:1, v:v). The amount of Cys formed was
linear with time and protein concentration in the ranges
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min at 37°C.
Determination of mRNA abundance
mRNA abundance for mat type I, alpha (mat1a), pemt
and gnmt in liver tissue was determined by qPCR. Total
RNA was extracted using a GenElute Mammalian Total
RNA kit (Sigma, Poole, Dorset, UK). First-strand cDNA
synthesis was carried out using a Reverse Transcription
System kit (Promega, Madison, WI, USA) and qPCR
was performed in a DNA Engine Opticon 3 Light cycler
(MJ Research, GMI Inc, Ramsay, MN, USA) using SYBR
Green Jump Start Taq Ready Mix (Sigma, Gillingham,
UK). Table 1 shows the forward and reverse oligonu-
cleotide primers used. Conditions for PCR were; dena-
turation at 94°C for 2 mins; 37 cycles of 94°C for 15
secs; annealing at 56°C for 1 min; final extension of 72°
C for 1 min; melting curve programme (60°C-95°C,
heating rate 0.2°C/sec). The threshold cycle values were
determined using Opticon Monitor 3 software quanti-
fied using the standard curve for each gene. Normaliza-
tion was performed using the Visual Basic Application
GeNorm [22].
Analytical methods
The triacylglycerol (TG) and cholesterol content of
plasma and liver lipid extracts was assayed using
enzyme-based kits (BPC BioSed S.r.l., Rome, Italy).
Plasma insulin was measured by ELISA (Mercodia,
Uppsala, Sweden). Protein concentrations were deter-
mined using commercial bicinchoninic acid reagent
(Pierce) (liver supernatants) or the method of Bradford
[23]. Plasma Hcy and Cys concentrations were measured
by HPLC with fluorometric detection [24].
Significance limits were calculated using Student’s
t test.
Results and discussion
Results
Liver TG concentrations were increased by about 2.6
fold in the rats fed the high fat diet as compared to the
control diet and there was a more modest, but signifi-
cant increase (+30%) in liver cholesterol levels (Table 2).
In rats fed the high fat diet plasma insulin levels were
about 6 fold higher than in animals given the control
diet (Figure 1A) and the HOMA-IR showed a rise of a
similar magnitude (Figure 1B). Plasma glucose levels,
however, were not significantly changed (control diet,
8.75 ± 0.70 mmol/l; high fat diet, 8.45 ± 0.27 mmol/l).
Plasma Hcy and Cys concentrations in control diet-
and high fat diet -fed rats are shown in Figure 2. Hcy
concentrations in the plasma of the rats fed the high fat
diet were significantly higher than those in control ani-
mals (+31%, P < 0.05) (Figure 2A), and this increase was
accompanied by a decrease in plasma Cys levels (-15%,
P < 0.001) (Figure 2B). In addition, the activities of both
CBS and CGL in the liver were significantly reduced by
high fat feeding (Figure 2). CBS activity was decreased by
about 15% (P < 0.05) (Figure 2C), while that of CGL was
lowered by approximately 23% (P < 0.05) (Figure 2D).
Determination of the relative abundance of mRNA
transcripts for MAT1A, PEMT and GNMT showed no
significant changes between the control and high fat-fed
groups (Table 3).
Discussion
Oxidative stress is now believed to be an important factor
in the development of NAFLD [3-5] acting as a cause as
well as a consequence of hepatic steatosis [6,25]. Here,
we investigated the changes which occur Hcy metabolism
in a high fat-diet induced model of NAFLD in rats. The
high fat diet used caused an increase in liver TG ( × 2.6)
and cholesterol (+ 30%) and plasma insulin levels and the
HOMA-IR were increased by 6 fold (Figure 1). These
results are in agreement with our previous more exten-
sive characterisation of the effects of this diet in inducing
Table 1 Primers used for qPCR
Gene name Gene product Gene Bank code/ID Forward Reverse
actb b-Actin NM_031144 gggaaatcgtgcgtgacatt gcggcagtggccatctc
alb Albumin NM_134326 catcctgaaccgtctgtgtg tttccaccaaggacccacta
b2m b2-Microglobulin NM_012512 atctgaggtgggtggaactg tgaccgtgatctttctggtg
Mat1a MAT-1A BC089770 cacccaggctacctggtaaa ccttcaaggctttcttgtgc
pemt PEMT NM_013003 ctcccaccttgctaccacat agctcccatttccttctggt
gnmt GNMT NM_017084 ggtgctcactctggtcacct gcctttgacaagtgggtcat
Table 2 Effect of high fat diet feeding on plasma TG and
cholesterol levels
Diet TG (mg/g liver) Cholesterol (mg/g liver)
Control diet 19.7 ± 4.8 31.8 ± 1.0
High fat diet 51.7 ± 5.6** 40.8 ± 2.6**
Rats were fed standard low fat diet (Control diet) or a high fat diet for 18
weeks. Blood samples were then collected and the concentration TG and
cholesterol in plasma was measured. Data are the mean from 6 (Control diet)
or 4 (High fat diet) animals. **P < 0.01 vs Control diet.
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model for the condition.
A number of studies have implicated HHcy in prema-
ture atherosclerosis development, and oxidative stress is
thought to be a major factor in this effect [11,12].
NAFLD is associated with accelerated atherosclerosis
[10], and oxidative stress is now believed to be an
important factor in the development/progression of the
condition [3-5]. Recent studies have indicated that
increased oxidative stress is an important trigger for
insulin resistance, which is believed to cause the distur-
bances in liver lipid metabolism that result in NAFLD.
The resulting fat accumulation is then thought to pro-
mote further production of reactive oxygen species, thus
oxidative stress can be considered to be both a cause
and a consequence of hepatic steatosis [1,6,25]. In the
liver, Hcy is produced from SAH formed during methyl
transfer reactions involving SAM and methyltransferase
enzymes such as GNMT and PEMT, and removed by
conversion to Cys via the transsulphuration pathway
which involves CBS and CGL [11-13]. Although it has
been shown that the plasma Hcy levels are elevated in
alcoholic fatty liver disease [26] and that HHcy is asso-
ciated with the development of hepatic steatosis in mice
deficient in CBS and in human subjects with a genetic
defect in the enzyme [14-16,27], few studies have inves-
tigated Hcy metabolism in NAFLD. Gulsen et al. [16]
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Figure 1 Effect of high fat diet feeding on plasma insulin and
HOMA-IR. Rats were fed standard low fat diet (Control diet) or a
high fat diet for 18 weeks. Blood samples were then collected and
the concentration of insulin in plasma (A) were determined and the
HOMA-IR (B) calculated. Data are the mean from 6 (Control diet) or
4 (High fat diet) animals and error bars show the SEM. **P < 0.01,
***P < 0.001 vs Control diet.
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Figure 2 Effect of high fat diet feeding on plasma homocysteine and liver CBS and CGL activities. Rats were fed a standard low fat
(Control diet) or a high fat diet for 18 weeks and blood samples and livers were then collected. A. Plasma Hcy; B. Plasma Cys; C. Liver CBS
activity; D. Liver CGL activity. Data are the mean from 6 (Control diet) or 4 (High fat diet) animals. Error bars show the SEM. *P < 0.05, ***P <
0.001 vs Control diet.
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nificantly higher in NAFLD patients as compared to
healthy subjects, and that they were a good predictor of
progression to NASH. In contrast, however, another
study found no significant difference in plasma Hcy
levels in obese subjects with or without NAFLD [28].
The results of our experiments show that plasma Hcy
is significantly increased in high fat diet-induced
NAFLD in rats, and that this change is accompanied by
a decrease in plasma Cys (Figure 2A,B), suggesting that
the transsulphuration pathway is affected. Determination
of the activities of the two enzymes of the pathway
showed that both are significantly down-regulated in
high fat diet-induced NAFLD (Figure 2C,D). We found
no evidence, however, for changes in the expression of
other key enzymes in the hepatic methionine cycle,
including MAT1A, the gene which encodes the catalytic
subunit of the isoenzymes MATI and MATIII which are
expressed in adult liver [29], and the methyltransferases
GNMT and PEMT (Table 3). Since these enzymes are
methyltransferases while CBS and CGL are lyases, it is
likely that they are regulated by different mechanisms.
In addition, we have only measured mRNA expression
for these enzymes, thus we cannot rule out the possibi-
lity that there may be post transcriptional changes
which modulate their activity in response to high fat
feeding. In contrast to our results, Kwon et al. [30] have
reported that CBS activity was unchanged in rats in
which NAFLD was induced by feeding a diet containing
71% of the energy as fat, while CGL activity was
increased by about 35%. In this study, however, the con-
trol diet contained 35% of energy from fat, which is con-
siderably higher than the 10% of energy from fat in our
control diet. Thus, our findings indicate that high fat
diet-induced NAFLD is associated with HHcy, and that
this is caused by reduced conversion to Cys via the
transsulphuration pathway, while the expression of
methyltransferases involved in liver methionine metabo-
lism is not changed. As it has been estimated that as
much as 50% of the Cys required for GSH synthesis is
formed from Hcy via this route, and the availability of
Cys is a limiting factor for GSH production [12,31], in
the long term this may lead to a decrease in body levels
of this antioxidant.
Conclusions
In conclusion, these results reported here show that
high fat diet-induced NAFLD in rats causes HHcy and
that this is due to down-regulation of hepatic CBS and
CGL activity. Thus, HHcy is an early feature of high fat
diet-induced NAFLD and is likely to contribute to the
increased risk of cardiovascular disease associated with
the condition.
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